FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions can be used for treating breast cancer. For this purpose, use of 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof as a therapeutic agent for treating breast cancer. Group of inventions also relates to use of 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for treating breast cancer.
EFFECT: group of inventions provides higher clinical effectiveness in breast cancer ensured by higher inhibitory activity of the declared compound in relation to breast cancer cells.
6 cl, 2 dwg, 1 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR BILE DUCT CANCER | 2016 |
|
RU2712222C2 |
| THERAPEUTIC AGENT FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2777535C2 |
| SALT OF MONOCYCLIC DERIVATIVE OF PYRIDINE AND CRYSTAL THEREOF | 2015 |
|
RU2658821C1 |
| MONOCYCLIC PYRIDINE DERIVATIVE | 2014 |
|
RU2645352C2 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
| N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
| COMBINATION OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS | 2017 |
|
RU2742033C2 |
| ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
